logo-loader
RNS
Clinigen Group PLC

Clinigen Group plc - Grant of Share Options and PDMR notification

RNS Number : 0132G
Clinigen Group plc
01 November 2018
 

1 November 2018

 

 

Grant of share options and PDMR notification

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 31 October 2018, the following Directors were granted share options over a total of 139,251 ordinary shares of
0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 31 October 2021 subject to the achievement of certain performance criteria.

Director/PDMR

Number of share options granted

Total number of share options now held

 

Total number of ordinary shares now held

Total number of ordinary shares (excluding share options) as % issued share capital

Shaun Chilton

106,007

424,427

 

320,044

0.24%

Martin Abell

33,244

217,054

 

19,404

0.01%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Shaun Chilton

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

213800OBIKGI2JYYS227

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Grant of Options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

106,007

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

106,007

Nil

 

f)

Date of the transaction

31 October 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Martin Abell

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

213800OBIKGI2JYYS227

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Grant of Options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

33,244

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

33,244

Nil

 

f)

Date of the transaction

31 October 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

-Ends-

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Martin Abell, Group Chief Financial Officer

Matt Parrish, Head of Investor Relations




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

 

 


RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw

Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

For more information, please visit www.clinigengroup.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFSUSUFFASELF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read